Entrada Therapeutics (TRDA) Total Current Liabilities (2020 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Total Current Liabilities of $19.2 million for Q1 2026, up 4.15% year-over-year from $18.4 million in Q1 2025, and down 21.5% quarter-over-quarter from $24.5 million in Q4 2025.
Entrada Therapeutics (TRDA) Total Current Liabilities (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $19.2 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 4.15% year-over-year to $19.2 million; the TTM figure through Mar 2026 stood at $19.2 million (up 4.15% YoY), while the FY2025 annual figure was $24.5 million, down 38.07% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $19.2 million, down from $24.5 million in the prior quarter.
- The five-year high for Total Current Liabilities was $173.9 million in Q1 2024, with the low at $15.4 million in Q1 2022.
- The 5-year median for Total Current Liabilities is $24.5 million (2025), against an average of $67.7 million.
- The sharpest annual moves came in 2023 and 2025: Total Current Liabilities jumped 856.79% in 2023, then slumped 89.4% in 2025.
- Entrada Therapeutics' Total Current Liabilities stood at $22.0 million in 2022, then surged by 622.72% to $158.8 million in 2023, then slumped by 75.14% to $39.5 million in 2024, then sank by 38.07% to $24.5 million in 2025, then retreated by 21.5% to $19.2 million in 2026.
- Business Quant data shows TRDA's Total Current Liabilities at $19.2 million in Q1 2026, $24.5 million in Q4 2025, and $24.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - | 21.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.37 Mn |
| Mar 31, 2026 | 19.20 Mn |
| Dec 31, 2025 | 24.45 Mn |
| Sep 30, 2025 | 24.02 Mn |
| Jun 30, 2025 | 19.80 Mn |
| Mar 31, 2025 | 18.43 Mn |
| Dec 31, 2024 | 39.48 Mn |
| Sep 30, 2024 | 70.60 Mn |
| Jun 30, 2024 | 85.81 Mn |
| Mar 31, 2024 | 173.94 Mn |
| Dec 31, 2023 | 158.80 Mn |
| Sep 30, 2023 | 165.43 Mn |
| Jun 30, 2023 | 125.94 Mn |
| Mar 31, 2023 | 147.59 Mn |
| Dec 31, 2022 | 21.97 Mn |
| Sep 30, 2022 | 21.55 Mn |
| Jun 30, 2022 | 18.08 Mn |
| Mar 31, 2022 | 15.43 Mn |
| Dec 31, 2021 | 6.72 Mn |
| Sep 30, 2021 | 7.16 Mn |